Yoshiaki Sagara

Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial

Tsutomu Takashima, Hirofumi Mukai, Fumikata Hara et al. · The Lancet Oncology · 2015 · 95 citations

Medicine, Oncology, Pharmacology +15

Aldehyde dehydrogenase 1 expression predicts poor prognosis in triple-negative breast cancer

Yasuyo Ohi, Yoshihisa Umekita, Takako Yoshioka et al. · Histopathology · 2011 · 84 citations · Full text

Medicine, Cancer Biology, Oncology +14

Artificial intelligence for breast cancer detection in mammography: experience of use of the ScreenPoint Medical Transpara system in 310 Japanese women

Michiro Sasaki, Mitsuhiro Tozaki, Alejandro Rodríguez‐Ruiz et al. · Breast Cancer · 2020 · 66 citations

Medicine, Computer Science, Radiology +13

Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies

Akira I. Hida, Yasuaki Sagara, Daisuke Yotsumoto et al. · Breast Cancer Research and Treatment · 2016 · 64 citations · Full text

Medicine, Immunology, Oncology +17

Efficacy and safety of an amino acid jelly containing coenzyme Q10 and l-carnitine in controlling fatigue in breast cancer patients receiving chemotherapy: a multi-institutional, randomized, exploratory trial (JORTC-CAM01)

Satoru Iwase, Takashi Kawaguchi, Daisuke Yotsumoto et al. · Supportive Care in Cancer · 2015 · 63 citations

Medicine, Oncology, Pharmacology +14